Pulmonary Cell News Volume 10.08 | Mar 04 2021

    0
    35






    2021-02-25 | PULCN 10.08


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 2.25 – 4 March, 2021
    TOP STORY

    The In Vitro Multilineage Differentiation and Maturation of Lung and Airway Cells from Human Pluripotent Stem Cell–Derived Lung Progenitors in 3D

    Researchers describe a strategy for directed differentiation of human pluripotent stem cells (hPSCs) into mature lung and airway epithelial cells obtained through maturation of NKX2.1+ hPSC-derived lung progenitors in a 3D matrix of collagen I in the absence of glycogen synthase kinase 3 inhibition.
    [Nature Protocols]

    Abstract

    Explore scientific events this March with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    Panaxydol Attenuates Ferroptosis against LPS-Induced Acute Lung Injury in Mice by Keap1-Nrf2/HO-1 Pathway

    In vivo, the role of panaxydol (PX) on lipopolysaccharide (LPS)-induced acute lung injury in mice was tested by determination of LPS-induced pulmonary inflammation, pulmonary edema and ferroptosis. In vitro, BEAS-2B cells were used to investigate the molecular mechanisms by which PX functions via determination of inflammation, ferroptosis and their relationship.
    [Journal of Translational Medicine]

    Full Article

    Evodiamine Alleviates Lipopolysaccharide‐Induced Pulmonary Inflammation and Fibrosis by Activating Apelin Pathway

    Scientists provided a basis for the protective effect and mechanism of evodiamine in LPS‐induced inflammation and suggest that it might be potential therapeutics in human pulmonary infections.
    [Phytotherapy Research]

    Abstract

    Chromatin Remodeling by the Histone Methyltransferase EZH2 Drives Lung Pre-Malignancy and Is a Target for Cancer Prevention

    Tobacco carcinogen transformed human bronchial epithelial lines were characterized for cytosine DNA methylation, transcriptome reprogramming, and the effect of inhibiting EZH2 and G9a on the transformed phenotype. The effects of targeting EZH2 and G9a on lung cancer prevention was assessed in the A/J mouse lung tumor model.
    [Clinical Epigenetics]

    Full Article

    FK228 Sensitizes Radioresistant Small Cell Lung Cancer Cells to Radiation

    Researchers uncovered that FK228 sensitized human radioresistant SCLC cells to radiation mainly through induction of chromatin decondensation and suppression of DNA damage signaling and repair.
    [Clinical Epigenetics]

    Full Article

    Maf1 Suppression of ATF5-Dependent Mitochondrial Unfolded Protein Response Contributes to Rapamycin-Induced Radio-Sensitivity in Lung Cancer Cell Line A549

    Investigators showed that Maf1 was required for rapamycin to increase radio-sensitivity in A549 lung cancer cells.
    [Aging]

    Full Article

    LSD1-Mediated Stabilization of SEPT6 Protein Activates the TGF-β1 Pathway and Regulates Non-small-Cell Lung Cancer Metastasis

    Lysine-specific histone demethylase 1 (LSD1) demethylated the Septin 6 (SEPT6) promoter to upregulate SEPT6, which activated TGF-β1 pathway, thereby promoting metastasis of NSCLC.
    [Cancer Gene Therapy]

    Abstract

    LINC01089 Functions as a ceRNA for miR-152-3p to Inhibit Non‐Small Lung Cancer Progression through Regulating PTEN

    Down-regulation of long intergenic non-protein coding RNA 01089 (LINC01089) promoted the progression of NSCLC through regulating miR-152-3p/PTEN axis.
    [Cancer Cell International]

    Full Article

    Lotus Leaf Flavonoids Induce Apoptosis of Human Lung Cancer A549 Cells through the ROS/p38 MAPK Pathway

    Lotus leaf flavonoids (LLF) were applied to human lung cancer A549 cells and human SCLC cells H446 in vitro to verify the effect of LLF on apoptosis in these cells through the ROS/p38 MAPK pathway.
    [Biological Research]

    Full Article

    Enter a contest to win a personalized lab coat by subscribing to Organoid News!
    REVIEWS

    Predictive Biomarkers of Anti-PD-1/PD-L1 Therapy in NSCLC

    The authors summarize the latest advances in the predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.
    [Experimental Hematology & Oncology]

    Full Article

    INDUSTRY AND POLICY NEWS

    FDA Expands Approval of Pfizer’s Lorbrena® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer

    The FDA approved Pfizer Inc.’s supplemental New Drug Application for LORBRENA®, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive NSCLC. LORBRENA® is now indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test.
    [Pfizer, Inc.]

    Press Release

    FEATURED EVENT

    Cell Symposia: 20 Years of the Human Genome – From Sequence to Substance

    April 11 – 13, 2021
    San Diego, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Cancer Immunosuppression

    University Hospital of Muenster – Münster, Germany

    Postdoctoral Position – M. tuberculosis Infection

    UT Health Science Center at Tyler – Tyler, Texas, United States

    Postdoctoral Fellow – p53 and Metabolism

    The Francis Crick Institute – London, England, United Kingdom

    Postdoctoral Fellow – Cancer Metabolism

    H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States

    Postdoctoral Fellowship – Lung Cancer Research

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter